This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
Prescribing Information for SARCLISA®▼ (isatuximab) can be found via the Product Card at the bottom of the page.
Curated Science
Stay up-to-date on Multiple Myeloma and our products related to the disease.
About Multiple Myeloma
.png/jcr:content/sarclisa-pd-image%20(2).png 767w, /.imaging/webp/sanofi-platform/img400x300/dam/hcp-portal-uk/home/NEW/Science/Curated-Science/Oncology/Oncology/multiple-myeloma/SARCLISA---Pd-Independent-UK-Real-World-Data/sarclisa-pd-image-(2).png/jcr:content/sarclisa-pd-image%20(2).png 1200w)
12:46
SARCLISA®▼(isatuximab)+ Pd Independent UK Real World Data
13:05
SARCLISA ®▼(isatuximab) in Clinical Practice: A Real World Case Study – Dr Karthik Ramasamy
16:34
SARCLISA ®▼(isatuximab) in Clinical Practice: A Real World Case Study – Dr Kenny Douglas
12:56
SARCLISA ®▼(isatuximab) in Clinical Practice: A Real World Case Study – Dr Ceri Bygrave
9:58
SARCLISA ®▼(isatuximab) in Clinical Practice: A Real World Case Study – Dr Jane Clark
4:48
Overview of the Safety and Efficacy Data from ICARIA-MM Trial
Relapsed Refractory Multiple Myeloma
MAT-XU-2202564(v1.0)
Date of Preparation: September 2023
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
